Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/2b randomized double-blind placebo-controlled study of amlitelimab in adults with nonresponsive celiac disease
MOH_2024-09-18_013587Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in celiac disease (6 arms), sponsored by Sanofi. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
amlitelimab
03
Conditions
celiac disease
Beyond the preview
Go deeper on MOH_2024-09-18_013587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-18_013587.